-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
February 9, 2021 /--- -- Researchers at the Center for Childhood Diabetes at the University of Colorado School of Medicine have found that an immune response to insulin can help identify patients most likely to develop type 1 diabetes.
study, published recently in the journal PNAS, measured the immune response of genetically prediscent type 1 diabetic individuals to naturally occurring insulin and hybrid insulin peptides.
because not all individuals with genetic susceptible people have type 1 diabetes, the researchers tried to examine the immune response of exocytocytes that may occur before the onset of clinical diabetes.
(Photo: www.pixabay.com) "We wanted to know why people develop type 1 diabetes, and this study helps provide more information and data on how individuals at genetic risk are moving toward clinical diagnosis," said Dr. Aaron Michels, who led the study.
ideally, patients want to treat the disease when it is active, so this is how we need to know when people in the field have an immune response to insulin-producing cells.
" researchers collect blood samples from adolescents at genetic risk every six months for two years.
reactions to mixed insulin peptides were associated with worsening blood sugar measurements and the development of type 1 diabetes.
results show that important progress has been made in identifying the risk of type 1 diabetes early and the potential for intervention.
the treatment used in the study has delayed the onset of clinical type 1 diabetes," said Michelle Mitchell, a researcher at the University of New China.
patients with these specific immune responses may benefit from immunological interventions to delay the onset of type 1 diabetes and may prevent it for years.
, Michels said, these results could lead to more studies than type 1 diabetes.
s focus is on diabetes, but it has implications for other autoimmune diseases," he said.
understanding the immune system's response is critical to trying to prevent disease before clinical symptoms appear.
" (Bioon.com) Source: Immune response to insulin can identify, help treat those at risk for type 1 diabetes Original source: Angela M. Mitchell et al. T-cell responses to hybrid insulin peptides prior to type 1 diabetes development, Proceedings of the National Academy of Sciences (2021). DOI: 10.1073/pnas.2019129118